+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Neuromyelitis optica and neuromyelitis optica like spectrum disorders: Is it not the time to change the criteria?



Neuromyelitis optica and neuromyelitis optica like spectrum disorders: Is it not the time to change the criteria?



Multiple Sclerosis and Related Disorders 20: 153




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065348979

Download citation: RISBibTeXText

PMID: 29414289

DOI: 10.1016/j.msard.2018.01.022


Related references

Neuromyelitis optica and neuromyelitis optica spectrum disorders: the evaluation of 86 patients followed by Istanbul Bilim University, Department of Neurology. Journal of the Neurological Sciences 357: E296-E297, 2015

Circulating Memory T Follicular Helper Cells in Patients with Neuromyelitis Optica/Neuromyelitis Optica Spectrum Disorders. Mediators of Inflammation 2016: 3678152, 2016

Clinical characteristics and follow-up of pediatric patients with neuromyelitis optica and neuromyelitis optica spectrum disorders. Zhonghua Er Ke Za Zhi 53(4): 268-273, 2015

Simulating the Impact of Elevated Levels of Interleukin-6 on the Pharmacokinetics of Various CYP450 Substrates in Patients with Neuromyelitis Optica or Neuromyelitis Optica Spectrum Disorders in Different Ethnic Populations. Aaps Journal 21(3): 42, 2019

Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate. Bmc Neurology 14: 51, 2014

Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up. Journal of the Neurological Sciences 372: 92-96, 2017

Peripheral CD19 + B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders. Journal of Neurology 266(1): 57-67, 2019

Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder. European Journal of Neurology 24(1): 219-226, 2017

Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder Patients in Turkish Cohort: Demographic, Clinical, and Laboratory Features. Neurologist 20(4): 61-66, 2015

Neuromyelitis optica and neuromyelitis optica spectrum disorder: Natural history and long-term outcome, an Indian experience. Journal of Neurosciences in Rural Practice 6(3): 331-335, 2015

The Efficacy and Tolerability of Mycophenolate Mofetil in Treating Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder in Western China. Clinical Neuropharmacology 39(2): 81-87, 2016

A descriptive study of prevalence, clinical features and other findings of neuromyelitis optica and neuromyelitis optica spectrum disorder in Khuzestan Province, Iran. Iranian Journal of Neurology 14(4): 204-210, 2015

Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset. Multiple Sclerosis 20(8): 1086-1094, 2014

Intractable cough as characteristic symptom of neuromyelitis optica and neuromyelitis optica spectrum disorder. Multiple Sclerosis 22(4): 576-577, 2016

Neuromyelitis optica-IgG testing in an Indian cohort with neuromyelitis optica and related demyelinating disorders: Our experience. Annals of Indian Academy of Neurology 16(3): 376-379, 2013